Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study

Abstract

Fecal calprotectin seems to be a reliable marker of relapse in quiescent Crohn's disease patients.

A prospective single‐centre evaluation of the intra‐individual variability of faecal calprotectin in quiescent Crohn's disease

“…Tibble et al 1 state that the greatest variability was at low concentrations, which may mean a clinically quiescent population, would yield more variability. The good correlation across three samples shown in our study provides reassurance that sam- 7 in colonic CD to define a risk of relapse with a good degree of accuracy (18.8-fold risk, sensitivity 80%, specificity 90.7%). The assay for FC used in this study differed from our own.…”

“…Data support its use in differentiating irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD), 1,[22][23][24][25] evaluating abdominal discomfort, 26 reducing the need for endoscopy in suspected IBD, 27 assessing treatment response in IBD, 14,15,[28][29][30] predicting relapse in IBD 7,8,[10][11][12][13] and predicting mucosal healing in IBD. 3,6,30,31 Indeed at our own institution, the monthly FC workload has increased from 50 samples a month in January 2007 to over 1000 per month in August 2012.…”

“…FC has been shown to have a homogenous distribution in human faeces, 5 supporting the notion that accurate analyses can be undertaken on a spot stool sample. It has been proposed that it may even be useful to predict mucosal healing at levels below threshold (50 μg/ g), 6 to potentially predict the risk of clinical relapse [7][8][9][10][11][12][13] or to monitor response to biological therapies. 14 However, these possibilities rely on the premise that levels of FC do not vary significantly from day to day in individual patients with CD.…”

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

“…In patients with quiescent CD, fecal calprotectin had a sensitivity of 80% and specificity 91% for predicting clinical relapse, with a threshold of 150 µg/g [61]. In a prospective study, Naismith et al ascertained using Bülhmann ELISA assay that a cut-off value of 240 µg/g had a significant predictive value of a high risk of clinical relapse within 12 months with an NPV of 96.8% [62].…”

Determinantes de la probabilidad de padecer enfermedades inflamatorias intestinales

“…Sin embargo, el curso de la enfermedad puede variar considerablemente. Recientemente, Kallel et al (2010) estudiaron 53 pacientes con EC en remisión clínica, excluyendo específicamente los pacientes con EC limitada a intestino delgado. En un periodo de 12 meses de seguimiento, el 18% desarrolló recaída clínica.…”